Company Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Mark Iwicki |
Contact Details
Address: 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 United States | |
| Phone | (678) 392-3419 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark T. Iwicki | Chief Executive Officer and Director |
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research and Development and Chief Medical Officer |
| David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer |
| Dr. John Adams Ph.D. | Chief Scientific Officer |
| Jeffrey J. Kagy | Chief Human Resources Officer |
| Chadwick J. Orevillo MPH | Executive Vice President and Head of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | EFFECT | Notice of Effectiveness |
| Jun 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 12, 2025 | ARS | Filing |
| May 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 12, 2025 | DEF 14A | Other definitive proxy statements |
| May 2, 2025 | PRE 14A | Other preliminary proxy statements |